- Home
- EXEL vs CCIA Comparison
EXEL vs CCIA Comparison
Compare EXEL & CCIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- CCIA
- Stock Information
- Founded
- EXEL 1994
- CCIA N/A
- Country
- EXEL United States
- CCIA
- Employees
- EXEL N/A
- CCIA N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- CCIA
- Sector
- EXEL Health Care
- CCIA
- Exchange
- EXEL Nasdaq
- CCIA Nasdaq
- Market Cap
- EXEL 10.4B
- CCIA N/A
- IPO Year
- EXEL 2000
- CCIA 2023
- Fundamental
- Price
- EXEL $40.44
- CCIA $25.50
- Analyst Decision
- EXEL Buy
- CCIA
- Analyst Count
- EXEL 22
- CCIA 0
- Target Price
- EXEL $44.00
- CCIA N/A
- AVG Volume (30 Days)
- EXEL 2.3M
- CCIA N/A
- Earning Date
- EXEL 10-28-2025
- CCIA N/A
- Dividend Yield
- EXEL N/A
- CCIA N/A
- EPS Growth
- EXEL 81.76
- CCIA N/A
- EPS
- EXEL 2.08
- CCIA N/A
- Revenue
- EXEL $2,230,005,000.00
- CCIA N/A
- Revenue This Year
- EXEL $9.19
- CCIA N/A
- Revenue Next Year
- EXEL $12.54
- CCIA N/A
- P/E Ratio
- EXEL $19.56
- CCIA N/A
- Revenue Growth
- EXEL 10.73
- CCIA N/A
- 52 Week Low
- EXEL $25.17
- CCIA N/A
- 52 Week High
- EXEL $49.62
- CCIA N/A
- Technical
- Relative Strength Index (RSI)
- EXEL 62.26
- CCIA 50.23
- Support Level
- EXEL $38.37
- CCIA $25.44
- Resistance Level
- EXEL $39.27
- CCIA $25.49
- Average True Range (ATR)
- EXEL 1.03
- CCIA 0.04
- MACD
- EXEL 0.38
- CCIA 0.01
- Stochastic Oscillator
- EXEL 92.53
- CCIA 71.43
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.